Q-omics provides the consensus-scored PNLDC1 profile across patient tissues and cancer cell-line models. PNLDC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PNLDC1 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, PNLDC1 RNA expression shows 12,080 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KICH, and TGCT as cancer lineages where PNLDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNLDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNLDC1 survival associations across molecular data types. PNLDC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNLDC1 RNA expression–survival associations across cancer types. High PNLDC1 expression shows unfavorable associations in MESO, KIRC and DLBC, but favorable associations in UCEC, HNSC and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify UCEC as the clearest survival context for PNLDC1 RNA expression.
This table summarizes PNLDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PNLDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNLDC1 shows lower tumor expression in KICH, LUAD, THCA and BLCA and higher tumor expression in HNSC and LUSC. The KICH box plot shows higher PNLDC1 RNA expression in normal versus tumor tissue (log2 FC = −0.856, t-test p < 0.001).
This table shows molecular features associated with PNLDC1 in patient tissues and cancer cell lines. In patient samples, PNLDC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PNLDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
